An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer

Hepato-Gastroenterology

Volumn 59, Issue 115, 2012, Pages 691-695

  Katayose, Yu ^a   Ohtsuka, Hideo ^a   Kitamura, Yo ^a   Masuda, Kunihiro ^a   Nakagawa, Kei ^a   Yamamoto, Kuniharu ^a   Yoshida, Hiroshi ^a   Onogawa, Tohru ^a   Motoi, Fuyuhiko ^a   Naitoh, Takeshi ^a   Rikiyama, Toshiki ^a   Egawa, Shin Ichi ^a   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; S 1; Second line

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GUANOSINE TRIPHOSPHATE; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOSIS; MALAISE; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OLFACTORY NERVE DISEASE; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; BILIARY TRACT SURGICAL PROCEDURES; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; RETROSPECTIVE STUDIES; TEGAFUR; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84860503082     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11530     Document Type: Article

References (13)

1. Chamberlain RS, Blumgart LH: Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol 2000; 7:55-66. (Pubitemid 30078495)
2. Unno M, Katayose Y, Rikiyama T, et al.: Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2009; 17:463-9.
3. Glimelius B, Hoffman K, Sjoden PO, et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600. (Pubitemid 26285639)
4. Takada T, Kato H, Matsushiro T, et al.: Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51:396-400. (Pubitemid 24255303)
5. Kubicka S, Rudolph KL, Tietze MK, et al.: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48:783-9. (Pubitemid 32619681)
6. Knox JJ, Hedley D, Oza A, et al.: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332-8. (Pubitemid 46218726)
7. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96:896-902. (Pubitemid 46452283)
8. Valle J, Wasan H, Palmer DH, et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273-81.
9. Okusaka T, Ishii H, Funakoshi A, et al.: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57:647-53. (Pubitemid 43237850)
10. Ueno H, Okusaka T, Ikeda M, et al.: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91:1769-74. (Pubitemid 39664963)
11. Furuse J, Okusaka T, Boku N, et al.: S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008; 62:849-55.
12. Yonemoto N, Furuse J, Okusaka T, et al.: A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37:843-51. (Pubitemid 350259003)
13. Sasaki T, Isayama H, Nakai Y, et al.: Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2010; (Epub ahead of print).